Clinical Trial Update: Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of allogeneic cellular vaccine 1650-G for non-small cell lung cancer completed; results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Allogeneic Cellular Vaccine 1650-G

Snippet

Sponsor: Edward Hirschowitz | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2013-05-20